Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
6.41
Nov 09 • 3:59 PM ET Dollar change+0.22 Percentage change(3.55%)
Aftermarket Close
6.32
Aftermarket • 7:30 PM ET Dollar change-0.09 Percentage change(-1.40%)
Index
RUT
Market Cap
363.18M
Enterprise Value
1.65B
Income
87.50M
Sales
1.02B
Book/sh
-10.81
Cash/sh
3.85
Employees
1850
IPO
Mar 22, 2022
P/E
4.32
Forward P/E
3.64
PEG
-
P/S
0.36
P/B
-
P/C
1.66
P/FCF
2.21
EV/EBITDA
5.09
EV/Sales
1.62
Quick Ratio
1.17
Current Ratio
1.68
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
1.48
EPS next Y
1.76
EPS next Q
0.29
EPS this Y
-37.76%
EPS next Y
-3.96%
EPS next 5Y
-12.88%
EPS past 3/5Y
-25.52% -
Sales past 3/5Y
-1.47% -0.10%
EPS Y/Y TTM
4.11%
Sales Y/Y TTM
-7.60%
EPS Q/Q
-53.64%
Sales Q/Q
-8.05%
Insider Own
8.24%
Insider Trans
2.38%
Inst Own
86.73%
Inst Trans
-18.99%
ROA
7.22%
ROE
-
ROIC
11.83%
Gross Margin
59.63%
Oper. Margin
26.38%
Profit Margin
8.59%
SMA20
-0.09%
SMA50
8.91%
SMA200
2.37%
Trades
Shs Outstand
56.66M
Shs Float
51.99M
52W High
14.91 -57.01%
52W Low
2.77 131.41%
Volatility
7.13% 5.11%
ATR (14)
0.34
RSI (14)
54.48
Beta
0.80
Rel Volume
0.48
Avg Volume
1.25M
Volume
604,261
Perf Week
3.55%
Perf Month
12.75%
Perf Quarter
31.35%
Perf Half Y
90.77%
Perf YTD
-46.04%
Perf Year
-53.52%
Perf 3Y
-56.31%
Perf 5Y
-
Perf 10Y
-
Prev Close
6.19
Price
6.41
Change %
3.55%
Consensus
Hold
Avg. Price Target
$4.00
Implied Upside
-37.6%
Analysts5incl. previous ratings
Rating Distribution0 Buy · 4 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 06, 2026Downgrade
BBTIG Research
Buy → Neutral
Apr 10, 2025Initiated
MFG logoMMizuho
Neutral$15+134.0%
Dec 02, 2024Upgrade
MS logoMMorgan Stanley
Underweight → Equal-Weight$13 → $20+212.0%
Nov 27, 2024Upgrade
BBTIG Research
Neutral → Buy$26+305.6%
Oct 20, 2023Initiated
WWolfe Research
Peer Perform
Jan 06, 2023Downgrade
MS logoMMorgan Stanley
Equal-Weight → Underweight$28+336.8%
Sep 08, 2022Initiated
BBTIG Research
Neutral
Aug 01, 2022Initiated
MS logoMMorgan Stanley
Equal-Weight$33+414.8%
Jun 21, 2022Initiated
BAC logoBBofA Securities
Underperform$25+290.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morris Milton MayoDirectorSep 04 '26Sale5.886,29336,97153,828Sep 08 05:13 PM
Morris Milton MayoDirectorSep 04 '26Proposed Sale5.866,29336,891Sep 04 03:07 PM
Kurdikar DevdattPresident and CEOAug 12 '26Buy4.7030,000140,937804,919Aug 13 10:50 AM
Elguicze JacobSVP and CFOAug 12 '26Buy4.6720,00093,360309,139Aug 13 10:48 AM
Mann Jeffrey ZPres, Pharm Svc&Prod Mgmt, CLOAug 12 '26Buy4.9920,00099,800262,915Aug 13 10:47 AM
HOMBACH ROBERT J.DirectorAug 12 '26Buy4.9745,000223,848109,587Aug 13 10:45 AM
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.
PresidentMr. Devdatt Kurdikar Ph.D.
Senior VP & CFOMr. Jacob P. Elguicze
Senior VPMr. Jeffrey Z. Mann
Senior VP & Chief Human Resources OfficerMs. Jean M. Casner
Senior Vice President of Global Manufacturing & Supply ChainMr. Shaun Curtis